All Fields
Computer Science
Medicine
FAQ
Contact
Sign in
diaminopyrimidine
Known as:
DAP
Â
Â
National Institutes of Health
Topic mentions per year
Topic mentions per year
1952-2017
0
5
10
15
1952
2016
Related topics
Related topics
3 relations
Narrower (2)
Minoxidil
Trimethoprim
Broader (1)
aminopyrimidine
Related mentions per year
Related mentions per year
1953-2019
1960
1980
2000
2020
diaminopyrimidine
Trimethoprim
Minoxidil
aminopyrimidine
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Characterization of three diaminopyrimidines as potent and selective antagonists of P2X3 and P2X2/3 receptors with in vivo efficacy in a pain model.
Elena Ballini
,
Caterina Virginio
,
+9 authors
Wolfgang Jarolimek
British journal of pharmacology
2011
BACKGROUND AND PURPOSE P2X3 and P2X2/3 receptors are highly localized on the peripheral and central pathways of nociceptive…Â
(More)
Is this relevant?
2009
2009
Dicer-1-dependent Dacapo suppression acts downstream of Insulin receptor in regulating cell division of Drosophila germline stem cells.
Jenn-Yah Yu
,
Steven H. Reynolds
,
+6 authors
Hannele Ruohola-Baker
Development
2009
It is important to understand the regulation of stem cell division because defects in this process can cause altered tissue…Â
(More)
Is this relevant?
2009
2009
Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.
Alam M Jahangir
,
Muzaffar Alam
,
+8 authors
Jeff Zira
Bioorganic & medicinal chemistry letters
2009
The purinoceptor subtypes P2X(3) and P2X(2/3) have been shown to play a pivotal role in models of various pain conditions…Â
(More)
Is this relevant?
2008
2008
Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections.
William J. Peppard
,
Christopher D Schuenke
Current opinion in investigational drugs
2008
Arpida Ltd, under license from Roche AG, is developing the diaminopyrimidine dihydrofolate reductase inhibitor iclaprim for the…Â
(More)
Is this relevant?
2007
2007
Binding thermodynamics of substituted diaminopyrimidine renin inhibitors.
Ronald W Sarver
,
Jeanette Peevers
,
+14 authors
Igor Mochalkin
Analytical biochemistry
2007
Renin is an aspartyl protease involved in the production of angiotensin II, a potent vasoconstrictor. Renin inhibitors can…Â
(More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Small molecules that induce cardiomyogenesis in embryonic stem cells.
Xu Wu
,
Sheng Ding
,
Qiang Ding
,
Nathanael S Gray
,
Peter G. Schultz
Journal of the American Chemical Society
2004
A phenotypic cell-based screen of a large combinatorial chemical library led to the identification of a class of…Â
(More)
Is this relevant?
2003
2003
Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria.
Peter Schneider
,
Stephen P Hawser
,
Khalid Islam
Bioorganic & medicinal chemistry letters
2003
Iclaprim, a new selective dihydrofolate inhibitor was synthesized based on rational drug design. Iclaprim's interaction with a…Â
(More)
Is this relevant?
1996
1996
Prebiotic synthesis of diaminopyrimidine and thiocytosine
Michael P. Robertson
,
Matthew Levy
,
S. L. Miller
Journal of Molecular Evolution
1996
The reaction of guanidine hydrochloride with cyanoacetaldehyde gives high yields (40–85%) of 2,4-diaminopyrimidine under the…Â
(More)
Is this relevant?
1994
1994
The sulfonamide-diaminopyrimidine story.
A S J P A M van Miert
Journal of veterinary pharmacology and…
1994
This paper is devoted to chemotherapy in the sense that Paul Ehrlich (Nobel Prize winner in 1908) coined the word: to describe…Â
(More)
Is this relevant?
1977
1977
Lipid-soluble diaminopyrimidine inhibitors of dihydrofolate reductase.
Charles A. Nichol
,
J C Cavallito
,
Joshua Woolley
,
Christophe Sigel
Cancer treatment reports
1977
On the basis of activity against experimental tumors and potency as inhibitors of human dihydrofolate reductase, two compounds…Â
(More)
Is this relevant?